Incannex Partners with AASM Foundation to Advance Sleep Apnea Research

Event summary

  • Incannex Healthcare has partnered with the AASM Foundation to sponsor a Focused Projects Grant for Junior Investigators dedicated to sleep apnea research, to be awarded in 2026.
  • The partnership supports Incannex's lead investigational drug IHL-42X, an oral fixed-dose combination for obstructive sleep apnea (OSA).
  • IHL-42X has received FDA Fast Track designation and is advancing into the Phase 2 DReAMzz study, with patient dosing expected to commence soon.
  • Incannex has established a Clinical Advisory Board of leading sleep medicine experts to guide its clinical strategy.

The big picture

Incannex's partnership with the AASM Foundation underscores its commitment to advancing sleep apnea research while strengthening its clinical pipeline. The collaboration aligns with broader industry trends toward combination therapies and targeted treatments for chronic conditions. With FDA Fast Track designation and a well-defined Phase 3 pathway, Incannex is positioning itself to address a significant unmet medical need in the sleep medicine market.

What we're watching

Clinical Progress
The pace at which the DReAMzz study optimizes IHL-42X's efficacy will determine its readiness for Phase 3 trials.
Regulatory Pathway
How the FDA Fast Track designation accelerates IHL-42X's development timeline and potential approval.
Market Opportunity
Whether Incannex can capitalize on the unmet need in OSA treatment to secure a competitive edge.

Related topics

Partnership